1. New Insulin Glargine 300 Units∙mL2-1 Provides a More Even Activity Profile and Prolonged Glycemic Control at Steady State Compared With Insulin Glargine 100 Units∙mL2-1
Featured Article:
Reinhard H.A. Becker, Raphael Dahmen, Karin Bergmann, Anne Lehmann, Thomas Jax, and Tim Heise
Diabetes Care
Volume 38:
April, 2015

2. STUDY OBJECTIVE
To characterize the pharmacokinetics (PK) and pharmacodynamics (PD) of a new insulin glargine comprising 300 units∙mL–1 (Gla-300), compared with insulin glargine 100 units ∙ mL–1 (Gla-100) at steady state in people with type 1 diabetes
Becker R.H.A. et al. Diabetes Care 2015;38:

3. STUDY DESIGN AND METHODS
Randomized, double-blind, crossover study applied the euglycemic clamp technique over 36 h
Participants received once-daily subcutaneous administrations of either 0.4 (cohort 1) or 0.6 units∙kg–1 (cohort 2) Gla-300 for 8 days in one treatment period and 0.4 units∙kg–1 Gla-100 for 8 days in the other
PK and PD assessments performed on the last treatment day included serum insulin measurements over 36 h
Becker R.H.A. et al. Diabetes Care 2015;38:

4. RESULTS
At steady state, insulin concentration and glucose infusion rate profiles of Gla-300 were more constant and more evenly distributed over 24 h than those of Gla-100 and lasted longer
Tight blood glucose control was maintained for approximately 5 h longer with Gla-300
Becker R.H.A. et al. Diabetes Care 2015;38:

5. Becker R.H.A. et al. Diabetes Care 2015;38:637-643

6. Becker R.H.A. et al. Diabetes Care 2015;38:637-643

7. Becker R.H.A. et al. Diabetes Care 2015;38:637-643

8. CONCLUSIONS
Gla-300 provides more even steady-state PK and PD profiles and a longer duration of action than Gla-100
Blood glucose control is extended well beyond 24 h
Becker R.H.A. et al. Diabetes Care 2015;38:

9. Becker R.H.A. et al. Diabetes Care 2015;38:637-643